Doctor and Woman Examining Pills Kathy Moscou, Jillian Clare Kohler, and Joel Lexchin

Pharmacovigilance in low and lower middle-income countries has not been commensurate with increasing access to medicines, despite growing  recognition that it is important to health outcomes. Pharmacovigilance is impeded where healthcare systems are overburdened and under-  resourced. In countries such as India, the population is increasingly exposed to potential adverse drug reactions. Pharmaceutical industry  corporate governance, that advances pharmacovigilance in under-resourced countries, would support postmarket drug safety. An analytic  framework is used to guide this comparative analysis of pharmacovigilance governance within global pharmaceutical corporations (GPCs) and  their Indian subsidiaries. Findings reveal that pharmacovigilance is not fully integrated into corporate governance of the GPCs studied. GPCs  exhibiting the least integration have more outstanding drug safety issues. Policy incentives would advance integration of corporate governance  and pharmacovigilance.